Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations

Surgery

Volumn 143, Issue 5, 2008, Pages 630-640

  Sarquis, Marta S ^a,b   Silveira, Leticia G ^a   Pimenta, Flavio J ^a   Dias, Eduardo P ^a,b   Teh, Bin T ^c   Friedman, Eitan ^d   Gomez, Ricardo S ^a   Tavares, Gabriela C ^a   Eng, Charis ^e   De Marco, Luiz ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b HOSPITAL FELÍCIO ROCHO   (Brazil)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFIBROMIN; PROTEIN;

ADULT; AGED; ARTICLE; BRAZIL; CANCER RISK; CLINICAL ARTICLE; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GERM LINE; HERITABILITY; HETEROZYGOSITY; HRPT2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; MUTATOR GENE; NONSENSE MUTATION; OUTCOME ASSESSMENT; PARATHYROID CARCINOMA; PARATHYROID TUMOR; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCREENING TEST; SEQUENCE ANALYSIS; SURGICAL APPROACH;

ADOLESCENT; ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; HUMANS; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 43049117445     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.12.012     Document Type: Article

References (39)

1. Marx S.J. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343 (2000) 1863-1875
2. Miedlich S., Krohn K., and Paschke R. Update on genetic and clinical aspects of primary hyperparathyroidism. Clin Endocrinol 59 (2003) 539-554
3. Carpten J.D., Robbins C.M., Villablanca A., Forsberg L., Presciuttini S., Bailey-Wilson J., et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32 (2002) 676-680
4. Szabo J., Heath B., Hill V.M., Jackson C.E., Zarbo R.J., Mallette L.E., et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56 (1995) 944-950
5. Simonds W.F., James-Newton L.A., Agarwal S.K., Yang B., Skarulis M.C., Hendy G.N., et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine 81 (2002) 1-26
6. Chen J.D., Morrison C., Zhang C., Kahnoski K., Carpten J.D., and Teh B.T. Hyperparathyroidism-jaw tumor syndrome. J Intern Med 253 (2003) 634-642
7. Cavaco B.M., Barros L., Pannett A.A., Ruas L., Carvalheiro M., Ruas M.M., et al. The hyperparathyroidism-jaw tumor syndrome in a Portuguese kindred. QJM 94 (2001) 213-222
8. Bradley K.J., Hobbs M.R., Buley I.D., Carpten J.D., Cavaco B.M., Fares J.E., et al. Uterine tumors are a phenotypic manifestation of the hyperparathyroidism-jaw tumor syndrome. J Intern Med 25 (2005) 18-26
9. Cetani F., Pardi E., Giovannetti A., Vignali E., Borsari S., Golia F., et al. Genetic analysis of the MEN1 gene and HRPT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clin Endocrinol 56 (2002) 457-464
10. Simonds W.F., Robbins C.M., Agarwal S.K., Hendy G.N., Carpten J.D., and Marx S.J. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89 (2004) 96-102
11. Villablanca A., Calender A., Forsberg L., Hoog A., Cheng J.D., Petillo D., et al. Germline and de novo mutations in the HRPT2 tumor suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41 (2004) e32
12. Bradley K.J., Cavaco B.M., Bowl M.R., Harding B., Cranston T., Fratter C., et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol 6 (2006) 299-306
13. Mizusawa N., Uchino S., Iwata T., Tsuyuguchi M., Suzuki Y., Mizukoshi T., et al. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol 65 (2006) 9-16
14. Yoshimoto K., Iwahana H., Fukuda A., Sano T., and Itakura M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Cancer 72 (1993) 1386-1393
15. Huang S.M., Duh Q.Y., Shaver J., Siperstein A.E., Kraimps J.L., and Clark O.H. Familial hyperparathyroidism without multiple endocrine neoplasia. World J Surg 21 (1997) 22-28
16. Teh B.T., Esapa C.T., Houlston R., Grandell U., Farnebo F., Nordenskjold M., et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet 63 (1998) 1544-1549
17. Honda M., Tsukada T., Tanaka H., Maruyama K., Yamaguchi K., Obara T., et al. A novel mutation of the MEN 1 gene in a Japanese kindred with familial isolated hyperparathyroidism. Eur J Endocrinol 142 (2000) 138-143
18. Kassem M., Kruse T.A., Wong F.K., Larsson C., and Teh B.T. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab 85 (2000) 165-167
19. Warner J., Epstein M., Sweet A., Singh D., Burgess J., Stranks S., et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41 (2004) 155-160
20. Cetani F., Pardi E., Ambrogini E., Lemmi M., Borsari S., Cianferotti L., et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol 64 (2006) 146-152
21. Wassif W.S., Moniz C.F., Friedman E., Wong S., Weber G., Nordenskjold M., et al. Familial isolated hyperparathyroidism: A distinct genetic entity and increased risk of parathyroid cancer. J Clin Endocrinol Metab 177 (1993) 1485-1489
22. Teh B.T., Farnebo F., Twigg S., Hoog A., Kytola S., Korpi-Hyovalti E., et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 83 (1998) 2114-2120
23. Haven C.J., Wong F.K., van Dam E.W., van der Juijt R., van Asperen C., Jansen J., et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 85 (2000) 1449-1454
24. Ohye H., Sato M., Matsubara S., Miyauchi A., Imachi H., Murao K., et al. Germline mutation of the multiple endocrine neoplasia type 1 (MEN1) gene in a family with primary hyperparathyroidism. Endocr J 45 (1998) 719-723
25. Sato M., Matsubara S., Miyauchi A., Ohye H., Imachi H., Murao K., et al. Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. J Med Genet 35 (1998) 915-919
26. Villablanca A., Wassif W.S., Smith T., Höög A., Vierimaa O., Kassem M., et al. Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol 147 (2002) 313-322
27. Pannett A.A., Kennedy A.M., Turner J.J., Forbes S.A., Cavaco B.M., Bassett J.H., et al. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol 58 (2003) 639-646
28. Carrasco C.A., Gonzalez A.A., Carvajal C.A., Campusano C., Oestreicher E., Arteaga E., et al. Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism. J Clin Endocrinol Metab 89 (2004) 4124-4129
29. Howell V.M., Haven C.J., Kahnoski K., Khoo S.K., Petillo D., Chen J., et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumors. J Med Genet 40 (2003) 657-663
30. Cetani F., Pardi E., Borsari S., Viacava P., Dipollina G., Cianferotti L., et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89 (2004) 5583-5591
31. Boom R., Sol C., Beld M., Weel J., Goudsmit J., and Wertheim-van Dillen P. Improved silica-guanidinium thiocyanate DNA isolation procedure based on selective binding of bovine alpha-casein to silica particles. J Clin Microbiol 37 (1993) 615
32. Shattuck T.M., Välimäki S., Obara T., Gaz R.D., Clark O.H., Shoback D., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349 (2003) 1722-1729
33. Tan M.H., Morrison C., Wang P., Yang X., Haven C.J., Zhang C., et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10 (2004) 6629-6637
34. Riss P., Kaczirek K., Heinz G., Bieglmayer C., and Niederle B. A "defined baseline" in PTH monitoring increases surgical success in patients with multiple gland disease. Surgery 142 (2007) 398-404
35. Shabtai M., Ben-Haim M., Muntz Y., Vered I., Rosin D., Kuriansky J., et al. 140 consecutive cases of minimally invasive, radio-guided parathyroidectomy: lessons learned and long-term results. Surg Endosc 17 (2003) 688-691
36. Carling T., and Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med 257 (2005) 27-37
37. Cetani F., Pardi E., Ambrogini E., Viacava P., Borsari S., Lemmi M., et al. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr Relat Cancer 14 (2007) 493-499
38. Woodard G.E., Lin L., Zhang J.H., Agarwal S.K., Marx S.J., and Simonds W.F. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24 (2005) 1272-1276
39. Juhlin C.C., Villablanca A., Sandelin K., Haglund F., Nordenstrom J., Forsberg L., et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14 (2007) 501-512